Abstract CT275: ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci
Institutions: Institut Paoli-Calmettes, Institut de Cancérologie de l'Ouest, UniCancer Group, Centre Léon Bérard, Centre Jean Perrin, Institut Gustave Roussy, Institut de Cancérologie de Lorraine, Institut Sainte Catherine, Institut Curie, Institut universitaire du cancer de Toulouse Oncopole, Institut Jean Godinot, Centre Oscar Lambret, Centre Antoine Lacassagne, Centre Georges François Leclerc, Institut Regional du Cancer de Montpellier, Institut de Cancérologie Strasbourg, Institut Bergonié, Centre François Baclesse
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154681379
Cites:
Cited by:
Related to: